Mind Medicine Inc
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials… Read more
Mind Medicine Inc (MNMD) - Net Assets
Latest net assets as of September 2025: $130.60 Million USD
Based on the latest financial reports, Mind Medicine Inc (MNMD) has net assets worth $130.60 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($236.92 Million) and total liabilities ($106.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $130.60 Million |
| % of Total Assets | 55.12% |
| Annual Growth Rate | 111.54% |
| 5-Year Change | 218.25% |
| 10-Year Change | N/A |
| Growth Volatility | 1174.05 |
Mind Medicine Inc - Net Assets Trend (2015–2024)
This chart illustrates how Mind Medicine Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mind Medicine Inc (2015–2024)
The table below shows the annual net assets of Mind Medicine Inc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $241.45 Million | +209.02% |
| 2023-12-31 | $78.13 Million | -48.23% |
| 2022-12-31 | $150.92 Million | -0.49% |
| 2021-12-31 | $151.66 Million | +99.91% |
| 2020-12-31 | $75.87 Million | +2670.96% |
| 2019-12-31 | $2.74 Million | -22.32% |
| 2018-12-31 | $3.52 Million | -10.70% |
| 2017-12-31 | $3.95 Million | +3001.10% |
| 2016-12-31 | $127.28K | -55.21% |
| 2015-12-31 | $284.17K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mind Medicine Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39856560100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $819.00K | 0.34% |
| Other Components | $639.51 Million | 264.86% |
| Total Equity | $241.45 Million | 100.00% |
Mind Medicine Inc Competitors by Market Cap
The table below lists competitors of Mind Medicine Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
$1.46 Billion |
|
Youngy Co Ltd
SHE:002192
|
$1.46 Billion |
|
Sichuan Tuopai Shede Wine Co Ltd
SHG:600702
|
$1.46 Billion |
|
Sineng Electric Co Ltd
SHE:300827
|
$1.46 Billion |
|
FRANKS INTL N.V. EO -01
F:FK2
|
$1.46 Billion |
|
Asmedia Technology Inc
TW:5269
|
$1.46 Billion |
|
Torm PLC Class A
NASDAQ:TRMD
|
$1.46 Billion |
|
Nanjing ESTUN Automation Co Ltd
SHE:002747
|
$1.46 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mind Medicine Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 78,134,000 to 241,448,000, a change of 163,314,000 (209.0%).
- Net loss of 108,679,000 reduced equity.
- New share issuances of 249,999,000 increased equity.
- Other comprehensive income increased equity by 476,000.
- Other factors increased equity by 21,518,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-108.68 Million | -45.01% |
| Share Issuances | $250.00 Million | +103.54% |
| Other Comprehensive Income | $476.00K | +0.2% |
| Other Changes | $21.52 Million | +8.91% |
| Total Change | $- | 209.02% |
Book Value vs Market Value Analysis
This analysis compares Mind Medicine Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 44.88x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.28x to 44.88x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $3.60 | $15.38 | x |
| 2016-12-31 | $1.58 | $15.38 | x |
| 2017-12-31 | $15.61 | $15.38 | x |
| 2018-12-31 | $11.28 | $15.38 | x |
| 2019-12-31 | $7.22 | $15.38 | x |
| 2020-12-31 | $4.27 | $15.38 | x |
| 2021-12-31 | $5.54 | $15.38 | x |
| 2022-12-31 | $4.89 | $15.38 | x |
| 2023-12-31 | $2.00 | $15.38 | x |
| 2024-12-31 | $0.34 | $15.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mind Medicine Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.25x
- Recent ROE (-45.01%) is above the historical average (-58.16%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -32.61% | 0.00% | 0.00x | 1.03x | $-121.07K |
| 2016 | -141.34% | 0.00% | 0.00x | 1.59x | $-192.63K |
| 2017 | -31.08% | 0.00% | 0.00x | 1.02x | $-1.62 Million |
| 2018 | -24.34% | 0.00% | 0.00x | 1.00x | $-1.21 Million |
| 2019 | -40.75% | 0.00% | 0.00x | 1.07x | $-1.39 Million |
| 2020 | -44.95% | 0.00% | 0.00x | 1.07x | $-41.69 Million |
| 2021 | -61.34% | 0.00% | 0.00x | 1.08x | $-108.20 Million |
| 2022 | -37.63% | 0.00% | 0.00x | 1.13x | $-71.89 Million |
| 2023 | -122.52% | 0.00% | 0.00x | 1.59x | $-103.55 Million |
| 2024 | -45.01% | 0.00% | 0.00x | 1.25x | $-132.82 Million |
Industry Comparison
This section compares Mind Medicine Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mind Medicine Inc (MNMD) | $130.60 Million | -32.61% | 0.81x | $1.46 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |